GlassScriptPhysician profile
Gerald J Milan
NPI 1801875992
$16,012.09
in general payments reported to CMS, 2019-2025
44 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,578 · 2020: $3,002 · 2021: $3,454 · 2022: $1,055 · 2023: $1,774 · 2024: $2,354 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,288 · Consulting Fee: $525 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,288.05 |
| Consulting Fee | $525.00 |
| Education | $109.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $4,653.94 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $2,883.38 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $1,080.53 | 2019-2025 | Velphoro, Velphoro, Optiflux |
| Baxter Healthcare | $862.00 | 2021 | |
| Vifor Pharma, INC. | $673.55 | 2019-2023 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $597.03 | 2019-2025 | Auryxia, Vafseo |
| Mallinckrodt Hospital Products INC. | $365.22 | 2022-2025 | Acthar |
| Ardelyx, INC. | $358.36 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $352.04 | 2019-2025 | Jynarque, Voyxact |
| Alnylam Pharmaceuticals INC. | $305.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $304.38 | 2021-2025 | Lupkynis |
| Zoll Medical Corporation | $300.00 | 2023 | |
| Vifor (International) LTD. | $300.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $277.49 | 2021-2025 | |
| Amgen INC. | $245.82 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Milan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.